Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Theralase Technologies News

    0,1224 $ +0,99% +0,0012 $
    In : 0,1143 € | 24.04.24 15:34:22 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0DLB7
    ISIN: CA88337V1004
    US-Symbol: TLTFF
    Typ: Aktie

    Theralase Technologies News

    28.04.21 - ACCESSWIRE
    Theralase Release FY2020 Audited Financial Statements
    TORONTO, ON / ACCESSWIRE / April 28, 2021 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    27.04.21 - ACCESSWIRE
    Theralase(R) Releases Quarterly Newsletter
    TORONTO, ON / ACCESSWIRE / April 27, 2021 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    09.04.21 - ACCESSWIRE
    Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
    TORONTO, ON / ACCESSWIRE / April 9, 2021 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    29.03.21 - ACCESSWIRE
    Theralase Launches Anti-Cancer Therapy Research Centre
    TORONTO, ON / ACCESSWIRE / March 29, 2021 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    25.03.21 - ACCESSWIRE
    Theralase Launches Sixth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
    TORONTO, ON / ACCESSWIRE / March 25, 2021 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    24.02.21 - ACCESSWIRE
    Theralase Launches Fifth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
    TORONTO, ON / ACCESSWIRE / February 24, 2021 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    01.02.21 - ACCESSWIRE
    Theralase(R) Releases Quarterly Newsletter
    TORONTO, ON / ACCESSWIRE / February 1, 2021 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    27.01.21 - ACCESSWIRE
    Theralase Launches Fourth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
    TORONTO, ON / ACCESSWIRE / January 27, 2021 /   Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    25.01.21 - ACCESSWIRE
    Theralase Launches Third Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
    TORONTO, ON / ACCESSWIRE / January 25, 2021 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    22.01.21 - ACCESSWIRE
    Theralase Expands Intellectual Property Portfolio
    TORONTO, ON / ACCESSWIRE / January 22, 2021 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    20.01.21 - ACCESSWIRE
    Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
    TORONTO, ON / ACCESSWIRE / January 20, 2021 / Theralase ® Technologies Inc. (" Theralase " or " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    19.01.21 - ACCESSWIRE
    Theralase Launches First Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
    TORONTO, ON / ACCESSWIRE / January 19, 2021 / Theralase ® Technologies Inc. (" Theralase " or " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    08.01.21 - ACCESSWIRE
    Theralase Announces Warrant Extension
    TORONTO, ON / ACCESSWIRE /   January 8, 2021 / Theralase ® Technologies Inc. (" Theralase " or " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical ...
    07.12.20 - ACCESSWIRE
    University of British Columbia Launched as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
    TORONTO, ON / ACCESSWIRE / December 7, 2020 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage ...
    27.11.20 - ACCESSWIRE
    CORRECTION: Theralase Releases 3Q2020 Financial Statements
    Correction of the press release published November 27, 2020. The release contained incorrect dates within the financial table. This has been corrected in the release below.
    27.11.20 - ACCESSWIRE
    Theralase Release 3Q2020 Financial Statements
    TORONTO, ON / ACCESSWIRE / November 27, 2020 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical-​stage ...
    23.11.20 - ACCESSWIRE
    Theralase Granted FDA Fast Track Designation for NMIBC Phase II Clinical Study
    TORONTO, ON / ACCESSWIRE / November 23, 2020 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage ...
    13.11.20 - PR Newswire
    IIROC Trading Resumption - TLT
    IIROC Trading Resumption - TLT Canada NewsWire
    13.11.20 - PR Newswire
    IIROC Trading Halt - TLT
    IIROC Trading Halt - TLT Canada NewsWire
    13.11.20 - ACCESSWIRE
    Theralase Technology Demonstrates High Kill Rate of Coronavirus (BSL-2)
    TORONTO, ON / ACCESSWIRE / November 13, 2020 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage ...

    Newssuche

    Videos

    24.04.24
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »